Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Operating Income (2016 - 2025)

China Pharma Holdings filings provide 16 years of Operating Income readings, the most recent being -$1.2 million for Q4 2025.

  • On a quarterly basis, Operating Income changed 0.35% to -$1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.2 million, a 29.41% increase, with the full-year FY2025 number at -$3.2 million, up 29.41% from a year prior.
  • Operating Income hit -$1.2 million in Q4 2025 for China Pharma Holdings, down from -$628145.0 in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $1.4 million in Q4 2022 to a low of -$1.4 million in Q2 2024.
  • Median Operating Income over the past 5 years was -$733245.0 (2021), compared with a mean of -$521061.7.
  • The widest YoY moves for Operating Income: up 79.18% in 2021, down 1104.13% in 2021.
  • China Pharma Holdings' Operating Income stood at $1.4 million in 2021, then increased by 3.25% to $1.4 million in 2022, then crashed by 43.28% to $797625.0 in 2023, then plummeted by 249.95% to -$1.2 million in 2024, then decreased by 0.35% to -$1.2 million in 2025.
  • The last three reported values for Operating Income were -$1.2 million (Q4 2025), -$628145.0 (Q3 2025), and -$652120.0 (Q2 2025) per Business Quant data.